Neuroendovascular robotics: wave of the future or failed promise?

In 2019, Siemens Healthineers (Erlangen, Germany) purchased Corindus Vascular Robotics, Inc (Waltham, Massachusetts, USA) for a staggering $1.1 billion. At the heart of this purchase was the CorPath GRX system which robotically assisted cardiac and neurointerventional therapy. It appeared the forefront of neuroendovascular robotics was coming into focus. However, in 2023, Siemens announced plans to scupper this newly acquired system at an estimated loss of $362 million as the "use of Corindus robots for cardiology operations did not fulfill our expectations". Robotic vascular intervention within the company transitioned to purely research and development.1 What happened and how did it happen so quickly? One could forgive the neurointerventional field if it cynically responded by paraphrasing Nietzsche with "endovascular robotics is dead". Did endovascular robotics promise too much, too quickly? Or was this simply a false start to a promising future? At the core of the matter is the question: How...
Source: Journal of NeuroInterventional Surgery - Category: Neurosurgery Authors: Tags: Editor ' s column Source Type: research